Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity

被引：0
|
作者：
E D Warlick
Q Cao
J Miller
机构：
[1] Oncology,Division of Hematology
[2] and Transplantation,undefined
[3] University of Minnesota Medical School,undefined
[4] Biostatistics and Informatics,undefined
[5] Masonic Cancer Center,undefined
[6] University of Minnesota,undefined
来源：
Leukemia | 2013年 / 27卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1789 / 1791
页数：2
相关论文
共 50 条
  • [21] The role of allogeneic transplantation in high-risk acute myelogenous leukemia
    Drobyski, WR
    LEUKEMIA, 2004, 18 (10) : 1565 - 1568
  • [22] A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities
    Chen, Yiming
    Kantarjian, Hagop
    Estrov, Zeev
    Faderl, Stefan
    Ravandi, Farhad
    Rey, Kristy
    Cortes, Jorge
    Borthakur, Gautam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (05): : 341 - 344
  • [23] Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells
    Machado-Neto, Joao Agostinho
    Campos, Paula de Melo
    Favaro, Patricia
    Lazarini, Mariana
    Lorand-Metze, Irene
    Costa, Fernando Ferreira
    Olalla Saad, Sara Teresinha
    Traina, Fabiola
    LEUKEMIA RESEARCH, 2014, 38 (02) : 251 - 257
  • [24] The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes
    Tsimberidou, Apostolia Maria
    Estey, Elihu
    Wen, Sijin
    Pierce, Sherry
    Kantarjian, Hagop
    Albitar, Maher
    Kurzrock, Razelle
    CANCER, 2008, 113 (07) : 1605 - 1613
  • [25] A phase II study with decitabine, low-dose cytarabine and G-CSF priming in high-risk myelodysplastic syndromes, refractory/relapsed acute myelogenous leukemia or acute myeloid leukemia in patients with significant comorbidities
    Butera, J.
    Winer, E.
    Wang, C.
    Castillo, J. J.
    Thomas, A. G.
    Safran, H.
    Mega, A. E.
    Colvin, G. A.
    Rathore, B.
    Quesenberry, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Treatment of patients with high-risk myelodysplastic syndromes
    Gattermann, Norbert
    Kuendgen, Andrea
    Germing, Ulrich
    CANCER TREATMENT REVIEWS, 2007, 33 : S64 - S68
  • [27] Stathmin 1 Is Involved In The Highly Proliferative Phenotype Of High-Risk Myelodysplastic Syndromes and Acute Leukemia Cells
    Machado-Neto, Joao Agostinho
    Campos, Paula de Melo
    Favaro, Patricia
    Lazarini, Mariana
    Lorand-Metze, Irene
    Costa, Fernando Ferreira
    Saad, Sara Teresinha Olalla
    Traina, Fabiola
    BLOOD, 2013, 122 (21)
  • [28] High-risk myelodysplastic syndromes in hypomethylants failure
    Gardin, Claude
    HEMATOLOGIE, 2010, 16 : 24 - 28
  • [29] Histopathology in the diagnosis of high-risk myelodysplastic syndromes
    Kayano, Hidekazu
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2018, 58 (02) : 51 - 60
  • [30] Part 5: Myelodysplastic syndromes-Treatment of high-risk disease
    Meira Magalhaes, Silvia Maria
    Lopes Ferrari Chauffaille, Maria de Lourdes
    Rodrigues Pereira Velloso, Elvira Deolinda
    Buzzini, Renata
    Bernardo, Wanderley Marques
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2018, 40 (03) : 278 - 282
12345